drugset / Trial / NCT06301386

Everolimus Combined With PD-1 in Advanced Colorectal Cancer Patients

NCT06301386 ↗

Phase 2 Not yet recruiting 25 enrolled Fudan University Anyang Tumor Hospital · collab
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical trial is to learn about efficacy of Everolimus in combination with PD-1 in patients with locally advanced and advanced colorectal cancer that cannot be R0 resected. The main question is to explore the survival time, safety and tolerability of the treatment. At the same time, the correlation between biomarkers (including PD-L1 expression, tumor mutation load, lymphocyte subpopulation, cytokines, TCR, intestinal microbes, and others) and the efficacy and drug resistance mechanism will be analyzed, so as to provide reference for the subsequent guidance of the screening of benefit groups.

Timeline

Start
2024-04-01
Primary completion
2026-05-01
Completion
2026-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Everolimus Small molecule — Oral

Indications